Page last updated: 2024-08-23

diltiazem and carteolol

diltiazem has been researched along with carteolol in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (33.33)18.2507
2000's3 (50.00)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ1
Hagihara, T; Kishi, Y; Matsumoto, G; Matsuo, H; Naka, K; Nanjo, K; Ohoshi, T; Sanke, T; Sasaki, H; Sowa, R1
Melena, J; Osborne, NN; Wood, JP1

Other Studies

6 other study(ies) available for diltiazem and carteolol

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
    Bioorganic & medicinal chemistry letters, 2005, Sep-15, Volume: 15, Issue:18

    Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride

2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
    Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6

    Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics

2010
Nicardipine may impair glucose metabolism in hypertensive diabetic patients.
    Diabetes research and clinical practice, 1994, Volume: 26, Issue:1

    Topics: Adult; Aged; Atenolol; Carteolol; Diabetes Mellitus, Type 2; Diltiazem; Enalapril; Female; Glucose; Glycated Hemoglobin; Humans; Hypertension; Male; Metoprolol; Middle Aged; Nicardipine; Propanolamines

1994
Betaxolol, a beta1-adrenoceptor antagonist, has an affinity for L-type Ca2+ channels.
    European journal of pharmacology, 1999, Aug-13, Volume: 378, Issue:3

    Topics: Adrenergic beta-Antagonists; Animals; Betaxolol; Binding, Competitive; Calcium Channels; Carteolol; Cerebral Cortex; Diltiazem; Dose-Response Relationship, Drug; Female; Male; Membranes; Nitrendipine; Propranolol; Radioligand Assay; Rats; Rats, Wistar; Stereoisomerism; Timolol; Tritium

1999